TXG Stock Recent News

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.

10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

10x Genomics (TXG) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.15 per share a year ago.

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. The company celebrated the successful launch of its cutting-edge platform, Xenium, which offers exceptional vision and surpasses competitors in speed, sensitivity, and specificity. 10x Genomics is poised for sustained growth with its pursuit of scientific advancements, expanding applications in various fields, and strategic partnerships.

10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has a huge growth opportunity in the genomics market thanks to its razor-blade business model and innovative product roadmap.

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor Relations and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Arias - Stifel Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Salem Salem - Barclays Tejas Savant - Morgan Stanley John Sourbeer - UBS Mason Carrico - Stephens Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Rachel Vatnsdal - JPMorgan Operator Thank you for standing by. My name is Aaron, and I will be your conference operator for today.